Literature DB >> 31599419

Long noncoding RNA CASC15 is upregulated in non-small cell lung cancer and facilitates cell proliferation and metastasis via targeting miR-130b-3p.

D-J Yu1, M Zhong, W-L Wang.   

Abstract

OBJECTIVE: Recent researches have discovered a class of long noncoding RNAs (lncRNAs), which are dysregulated in various tumors and linked to carcinogenesis. This study aims to uncover the molecular functions of lncRNA CASC15 in non-small cell lung cancer (NSCLC) tumorigenesis. PATIENTS AND METHODS: Real Time-quantitative Polymerase Chain Reaction (RT-qPCR) was performed to detect CASC15 expression in 55 NSCLC samples and four NSCLC cell lines. Besides, the function of CASC15 was detected through proliferation assay, transwell assay, and wound healing assay in NSCLC cells. Furthermore, the interaction between CASC15 and miR-130b-3p in NSCLC was studied by performing dual-luciferase reporter assay. In addition, tumor formation and metastasis assay were performed in vivo.
RESULTS: CASC15 expression was remarkably upregulated in NSCLC samples compared with that in adjacent samples. Cell proliferation, invasion, and migration in NSCLC were inhibited via knockdown of CASC15 in vitro. Moreover, RT-qPCR results revealed that miR-130b-3p was upregulated via knockdown of CASC15 in vitro. In addition, miR-130b-3p was a direct target of CASC15 in NSCLC. Tumor formation and metastasis were inhibited after CASC15 was knockdown in vivo.
CONCLUSIONS: Our study indicates that CASC15 could promote metastasis and proliferation of NSCLC through sponging miR-130b-3p in vitro and in vivo, which may offer a new therapeutic intervention for NSCLC patients.

Entities:  

Year:  2019        PMID: 31599419     DOI: 10.26355/eurrev_201909_19010

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  9 in total

1.  A study of the prognostic value of long non-coding RNA CASC15 in human solid tumors utilizing The Cancer Genome Atlas (TCGA) datasets and a meta-analysis.

Authors:  Weiwei Chen; Wenqi Qian; Jun Nie; Mintao Dai
Journal:  Clin Exp Med       Date:  2022-02-01       Impact factor: 3.984

2.  MALAT1 Promotes Cell Tumorigenicity Through Regulating miR-515-5p/EEF2 Axis in Non-Small Cell Lung Cancer.

Authors:  Feng Rong; Liang Liu; Can Zou; Jing Zeng; Yasheng Xu
Journal:  Cancer Manag Res       Date:  2020-08-24       Impact factor: 3.989

3.  LINC01089 functions as a ceRNA for miR-152-3p to inhibit non-small lung cancer progression through regulating PTEN.

Authors:  Huixian Zhang; Hao Zhang; Xingya Li; Siyuan Huang; Qianqian Guo; Di Geng
Journal:  Cancer Cell Int       Date:  2021-03-02       Impact factor: 5.722

4.  HOTAIR Facilitates Endocrine Resistance in Breast Cancer Through ESR1/miR-130b-3p Axis: Comprehensive Analysis of mRNA-miRNA-lncRNA Network.

Authors:  Mingdi Zhang; Kejin Wu; Peng Zhang; Yiran Qiu; Fang Bai; Hongliang Chen
Journal:  Int J Gen Med       Date:  2021-08-18

Review 5.  MicroRNAs as Predictors of Lung-Cancer Resistance and Sensitivity to Cisplatin.

Authors:  Maria Konoshenko; Yuriy Lansukhay; Sergey Krasilnikov; Pavel Laktionov
Journal:  Int J Mol Sci       Date:  2022-07-08       Impact factor: 6.208

6.  Identification of an autophagy-related 12-lncRNA signature and evaluation of NFYC-AS1 as a pro-cancer factor in lung adenocarcinoma.

Authors:  Fang Tong; Lifa Xu; Sheng Xu; Mingming Zhang
Journal:  Front Genet       Date:  2022-08-11       Impact factor: 4.772

7.  LncRNA MALAT1 accelerates non-small cell lung cancer progression via regulating miR-185-5p/MDM4 axis.

Authors:  Dan Wang; Suhong Zhang; Min Zhao; Fengling Chen
Journal:  Cancer Med       Date:  2020-11-04       Impact factor: 4.452

8.  The lncRNAs MIR600HG and TSPOAP1-AS1 may potentially act as biomarkers for predicting pancreatic cancer.

Authors:  Jing Tian; Yuanliang Wang
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

9.  Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma.

Authors:  Jie Ren; Aman Wang; Jiwei Liu; Qihang Yuan
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.